Age‐related EBV‐associated B‐cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti‐PD‐L1 antibody clone SP142

2020 ◽  
Vol 70 (8) ◽  
pp. 481-492 ◽  
Author(s):  
Ayako Sakakibara ◽  
Kei Kohno ◽  
Eri Ishikawa ◽  
Yuka Suzuki ◽  
Satoko Shimada ◽  
...  
Keyword(s):  
B Cell ◽  
Immune Escape ◽  
Lymphoproliferative Disorders ◽  
Lymphoproliferative Diseases ◽  
Age Related

Age-related EBV-associated B-cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entity

2009 ◽  
Vol 59 (12) ◽  
pp. 835-843 ◽  
Author(s):  
Yoshie Shimoyama ◽  
Naoko Asano ◽  
Masaru Kojima ◽  
Satoko Morishima ◽  
Kazuhito Yamamoto ◽  
...  
Keyword(s):  
B Cell ◽  
Lymphoproliferative Disorders ◽  
Diagnostic Approach ◽  
Age Related

scholarly journals 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders

Blood ◽  
1994 ◽  
Vol 84 (3) ◽  
pp. 733-738 ◽  
Author(s):  
S O'Brien ◽  
R Kurzrock ◽  
M Duvic ◽  
H Kantarjian ◽  
S Stass ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
Median Number ◽  
Lymphoproliferative Disorders ◽  
Lymphoproliferative Diseases ◽  
Prior Therapy ◽  
Heterogenous Group ◽  
Daily Dose ◽  
T Cell Malignancies

Abstract Mature T-cell lymphoproliferative disorders comprise a heterogenous group of diseases for which there is no standard therapy. These disorders are uncommon, and are usually treated similarly to their B- cell counterparts, but with less success. Nucleoside analogues have proven effective in indolent B-cell disorders but have been less well explored in T-cell malignancies. We treated 22 patients with mature T- cell lymphoproliferative diseases with 2-chlorodeoxyadenosine (2-CDA) administered as a continuous infusion at a daily dose of 4 mg/m2 over 7 days. Nineteen of the patients had received prior therapy with a median number of prior regimens of three. Eleven patients had leukemia or large granular lymphocytosis, eight patients had mycosis fungoides, and three had T-cell lymphoma. Nine patients (41%) responded to 2-CDA. Four of the patients had responses that were complete remissions, and three of these four patients remain in remission at 23, 24, and 23 months. The only important toxic effects were fever or infection, seen during 38% of courses. In conclusion, 2-CDA appears to be an effective therapy in T-cell lymphoproliferative disorders and deserves wider evaluation in this subset of patients.

scholarly journals Age-related EBV-associated B-cell lymphoproliferative disorders of the minor salivary gland: a case report

2016 ◽  
Vol 2 (3) ◽  
pp. 27-30
Author(s):  
Hiroyuki Makihara ◽  
Mitsuo Goto ◽  
Hiroshi Watanabe ◽  
Yoshihiko Sugita ◽  
Yoshiko Ariji ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Case Report ◽  
B Cell ◽  
Minor Salivary Gland ◽  
Lymphoproliferative Disorders ◽  
Age Related

Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders in elderly White patients

2010 ◽  
Vol 57 (2) ◽  
pp. 320-323 ◽  
Author(s):  
Stanislas Nimubona ◽  
Marc Bernard ◽  
Sophie De Guibert ◽  
Hélène Duval ◽  
Sylvie Caulet-Maugendre ◽  
...  
Keyword(s):  
B Cell ◽  
Epstein Barr Virus ◽  
Lymphoproliferative Disorders ◽  
Barr Virus ◽  
Age Related ◽  
Epstein Barr ◽  
White Patients

scholarly journals Overexpression of Activation-Induced Cytidine Deaminase in MTX- and Age-Related Epstein-Barr Virus-Associated B-Cell Lymphoproliferative Disorders of the Head and Neck

2015 ◽  
Vol 2015 ◽  
pp. 1-12 ◽  
Author(s):  
Kentaro Kikuchi ◽  
Toshiyuki Ishige ◽  
Fumio Ide ◽  
Yumi Ito ◽  
Ichiro Saito ◽  
...  
Keyword(s):  
B Cell ◽  
Epstein Barr Virus ◽  
Somatic Hypermutation ◽  
Cytidine Deaminase ◽  
B Cell Lymphoma ◽  
Lymphoproliferative Disorders ◽  
Barr Virus ◽  
Age Related ◽  
Activation Induced Cytidine Deaminase ◽  
Epstein Barr

Recent research has shown that activation-induced cytidine deaminase (AID) triggers somatic hypermutation and recombination, in turn contributing to lymphomagenesis. Such aberrant AID expression is seen in B-cell leukemia/lymphomas, including Burkitt lymphoma which is associated withc-myctranslocation. Moreover, Epstein-Barr virus (EBV) latent membrane protein-1 (LMP-1) increases genomic instability through early growth transcription response-1 (Egr-1) mediated upregulation of AID in B-cell lymphoma. However, few clinicopathological studies have focused on AID expression in lymphoproliferative disorders (LPDs). Therefore, we conducted an immunohistochemical study to investigate the relationship between AID and LMP-1 expression in LPDs (MTX-/Age-related EBV-associated), including diffuse large B-cell lymphomas (DLBCLs). More intense AID expression was detected in LPDs (89.5%) than in DLBCLs (20.0%), and the expression of LMP-1 and EBER was more intense in LPDs (68.4% and 94.7%) than in DLBCLs (10.0% and 20.0%). Furthermore, stronger Egr-1 expression was found in MTX/Age-EBV-LPDs (83.3%) than in DLBCLs (30.0%). AID expression was significantly constitutively overexpressed in LPDs as compared with DLBCLs. These results suggest that increased AID expression in LPDs may be one of the processes involved in lymphomagenesis, thereby further increasing the survival of genetically destabilized B-cells. AID expression may be a useful indicator for differentiation between LPDs and DLBCLs.

scholarly journals Diagnostic criteria of lymphoproliferative diseases from the peripheral blood samples using a cell biochip

2021 ◽  
Vol 49 ◽  
Author(s):  
O. S. Fedyanina ◽  
Yu. Yu. Chuksina ◽  
A. N. Khmelevskaya ◽  
A. N. Khvastunova ◽  
Yu. N. Matveev ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
B Cell ◽  
Peripheral Blood ◽  
Mononuclear Cells ◽  
Lymphoproliferative Disorders ◽  
Lower Proportion ◽  
Healthy Controls ◽  
Lymphoproliferative Diseases ◽  
Healthy Donors ◽  
A Cell

Background: At present, the diagnosis of lymphoproliferative disorders is based on the combination of blood or bone marrow smear morphology and immunophenotyping by flow cytometry. Immunophenotypic testing by flow cytometry technique is available only in big medical centers, which is not always convenient for a  patient. Therefore, development of an available method for preliminary diagnosis of lymphoproliferative diseases not requiring special equipment seems relevant.Materials and methods: Peripheral blood mononuclear cells from 17  patients admitted to the hospital with suspicion of a  lymphoproliferative disorder, and 17  healthy donors were studied on a cell biochip for determination of proportions of cells positive for various surface CD antigens. The diagnosis was verified by flow cytometry.Results: Compared to healthy controls and patients with T-cell lymphoproliferative disorders (TCLPD), the patients with B-cell lymphoproliferative disorders (BCLPD) had significantly lower proportion of CD7+ cells (medians, 7% and 73% respectively, p=2×10-6 for comparison with healthy controls; median  7% and 93% for comparison with TCLPD, p=0.032). In addition, the patients with BCLPD had higher proportion of peripheral СD19+ mononuclear cells, compared to that in the patients with TCLPD and healthy donors (medians 84% and 13% for comparison between BCLPD and healthy control, p=2×10-5; 84% and 3% for comparison of BCLPD and TCLPD, p=0.033). The patients with B-cell chronic lymphocytic leukemia had significantly higher CD5+ cells in the cell biochip compared to the patients with other BCLPD (medians 72% and 9%, p=0.024). The patients with TCLPD had significantly lower proportion of CD19+ cells than the healthy controls (medians, 3% and 13%, respectively, р=0.042).Conclusion: The study has demonstrated the potential to use the previously developed cell biochip for diagnosis of lymphoproliferative diseases. The biochip makes it possible to sort out white blood cells according to their surface differentiation antigen for their further morphological analysis. The cell biochip allows for the differential diagnosis between BCLPD and TCLPD and determination the lymphocyte clones based on the expression of immunoglobulin light chains.

scholarly journals Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients

2007 ◽  
Vol 13 (17) ◽  
pp. 5124-5132 ◽  
Author(s):  
Takashi Oyama ◽  
Kazuhito Yamamoto ◽  
Naoko Asano ◽  
Aya Oshiro ◽  
Ritsuro Suzuki ◽  
...  
Keyword(s):  
B Cell ◽  
Lymphoproliferative Disorders ◽  
Age Related ◽  
Group A

scholarly journals Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: Special references to lymphomas surrounding this newly recognized clinicopathologic disease

2008 ◽  
Vol 99 (6) ◽  
pp. 1085-1091 ◽  
Author(s):  
Yoshie Shimoyama ◽  
Kazuhito Yamamoto ◽  
Naoko Asano ◽  
Takashi Oyama ◽  
Tomohiro Kinoshita ◽  
...  
Keyword(s):  
B Cell ◽  
Epstein Barr Virus ◽  
Lymphoproliferative Disorders ◽  
Barr Virus ◽  
Age Related ◽  
Epstein Barr
Sign in / Sign up

Export Citation Format

Share Document